In vitro studies of dasatinib, its targets and predictors of sensitivity

Pigment Cell and Melanoma Research

Volumn 24, Issue 2, 2011, Pages 386-389

  Jilaveanu, Lucia B ^a   Zito, Christopher R ^a   Aziz, Saadia A ^a   Chakraborty, Ashok ^a   Davies, Michael A ^b   Camp, Robert L ^c   Rimm, David L ^c   Dudek, Arkadiusz ^d   Sznol, Mario ^a   Kluger, Harriet M ^a  

^a YALE CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAVEOLIN 1; DASATINIB; HEMATOPOIETIC CELL KINASE; PROTEIN KINASE FYN; PROTEIN KINASE LCK; PROTEIN KINASE LYN; PROTEIN KINASE YES; PROTEIN TYROSINE KINASE; STEM CELL FACTOR RECEPTOR;

CELL ADHESION; CELL DIFFERENTIATION; CELL GROWTH; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CELL SURVIVAL; CONCENTRATION RESPONSE; DRUG SENSITIVITY; DRUG TARGETING; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; IN VITRO STUDY; LETTER; LEUKEMIA; MELANOMA; METASTASIS INHIBITION; PROTEIN DETERMINATION; PROTEIN EXPRESSION; TISSUE MICROARRAY;

CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; MELANOMA; PROTEIN KINASE INHIBITORS; PYRIMIDINES; SKIN NEOPLASMS; SRC-FAMILY KINASES; THIAZOLES;

EID: 79952598575     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/j.1755-148X.2011.00835.x     Document Type: Letter

References (11)

1. Barnekow, A., Paul, E., and Schartl, M. (1987). Expression of the c-src protooncogene in human skin tumors. Cancer Res. 47, 235-240.
2. Buettner, R., Mesa, T., Vultur, A., Lee, F., and Jove, R. (2008). Inhibition of Src family kinases with dasatinib blocks migration and invasion of human melanoma cells. Mol. Cancer Res. 6, 1766-1774.
3. Demetri, G.D., Lo Russo, P., Macpherson, I.R., Wang, D., Morgan, J.A., Brunton, V.G., Paliwal, P., Agrawal, S., Voi, M., and Evans, T.R. (2009). Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors. Clin. Cancer Res. 15, 6232-6240.
4. Huang, J., Asawa, T., Takato, T., and Sakai, R. (2003). Cooperative roles of Fyn and cortactin in cell migration of metastatic murine melanoma. J. Biol. Chem. 278, 48367-48376.
5. Huang, F., Reeves, K., Han, X., Fairchild, C., Platero, S., Wong, T.W., Lee, F., Shaw, P., and Clark, E. (2007). Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res. 67, 2226-2238.
6. Jilaveanu, L.B., Zito, C.R., Aziz, S.A., Conrad, P.J., Schmitz, J.C., Sznol, M., Camp, R.L., Rimm, D.L., and Kluger, H.M. (2009). C-Raf is associated with disease progression and cell proliferation in a subset of melanomas. Clin. Cancer Res. 15, 5704-5713.
7. Kluger, H.M., Dudek, A.Z., Mccann, C., Ritacco, J., Southard, N., Jilaveanu, L.B., Molinaro, A., and Sznol, M. (2010). A phase 2 trial of dasatinib in advanced melanoma. Cancer .
8. Konecny, G.E., Glas, R., Dering, J. et al. (2009). Activity of the multikinase inhibitor dasatinib against ovarian cancer cells. Br. J. Cancer 101, 1699-1708.
9. Loganzo Jr, F., Dosik, J.S., Zhao, Y., Vidal, M.J., Nanus, D.M., Sudol, M., and Albino, A.P. (1993). Elevated expression of protein tyrosine kinase c-Yes, but not c-Src, in human malignant melanoma. Oncogene 8, 2637-2644.
10. Wary, K.K., Mariotti, A., Zurzolo, C., and Giancotti, F.G. (1998). A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth. Cell 94, 625-634.
11. Wellbrock, C., and Schartl, M. (2000). Activation of phosphatidylinositol 3-kinase by a complex of p59fyn and the receptor tyrosine kinase Xmrk is involved in malignant transformation of pigment cells. Eur. J. Biochem. 267, 3513-3522.